WO2003099288A1 - Composition medicinale - Google Patents
Composition medicinale Download PDFInfo
- Publication number
- WO2003099288A1 WO2003099288A1 PCT/JP2003/006596 JP0306596W WO03099288A1 WO 2003099288 A1 WO2003099288 A1 WO 2003099288A1 JP 0306596 W JP0306596 W JP 0306596W WO 03099288 A1 WO03099288 A1 WO 03099288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxyimidoformamidine
- phenyl
- cyclodextrin
- chloro
- morpholin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 229920000858 Cyclodextrin Polymers 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 19
- 239000007924 injection Substances 0.000 claims description 19
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- -1 phenyl- Chemical group 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920003255 poly(phenylsilsesquioxane) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the present invention can dissolve and contain V- (3-chloro-4-morpholine-4-yl) phenyl-hydroxyimidoformamidine at a high concentration, improve drug stability and improve quality. It relates to a pharmaceutical composition.
- iV- (3-chloro-4-4-morpholin-4-yl) phenyl-iV'-hydroxyimidoformamidine is a compound disclosed in TO01 / 32164, and selectively binds 20-HETE-producing enzyme. It has been shown to be effective for renal diseases, cardiovascular diseases, and cerebrovascular diseases (particularly cerebral infarction).
- solubilization suitable for each drug is extremely difficult, and even if it can be solubilized, it may become a problem with stability over time or in terms of safety. Various problems may occur.
- A- (3-chloro-4-4-morpholine_4-isole) phenyl-N, -hydroxyimidoformamidine is preferably administered by the intravenous route, but is very poorly soluble in water and unstable in acidic solutions. Therefore, it is inappropriate to be solubilized as an acidic salt, and it is unstable to light in a solution state. Another action was needed.
- long-term administration by intravenous drip infusion may be considered to prevent or treat cerebral infarction, and it is necessary to give due consideration to the safety of the living body when formulating the product.
- An object of the present invention is to provide a solution containing T- (3-chloro-4--4-morpholin-4-yl) phenyl- ⁇ -hydroxyimidoformamidine in a dissolved form at a high concentration, to provide stability over time,
- An object of the present invention is to provide a pharmaceutical composition which is excellent in stability against heat and light irradiation and is safe for a living body.
- the present inventors have conducted various studies to achieve the above object, and have found that A ⁇ -(3-chloro-4-morpholine-4-yl) phenyl-V'-hydroxyimidoformamidine has sulfobutyl ether / By adding 3-cyclodextrin or its salt, the drug can be dissolved and contained at a high concentration, the stability of the drug to heat and light irradiation is improved, and there is no damage to the living body due to administration We found that a safe formulation could be obtained. The present invention has been completed based on this finding.
- the present invention relates to a medicament comprising a pharmaceutically effective amount of V- (3-clo-4--4-morpholin-4-yl) phenyl-N, -hydroxyimidoformamidine, and sulfobutyl ether ⁇ -cyclodextrin or a salt thereof.
- a composition is provided.
- the pharmaceutical composition of the present invention can further guarantee long-term stability by freeze-drying.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically effective amount of V- (3-clo-4--4-morpholin-4-yl) phenyl-T'-hydroxyimidoformamidine, and sulfobutyl ether / 3-cyclodextrin or a salt thereof.
- V- (3-clo-4--4-morpholin-4-yl) phenyl-T'-hydroxyimidoformamidine and sulfobutyl ether / 3-cyclodextrin or a salt thereof.
- V- (3-chloro-4-4-morpholin-4-yl) phenyl-hydroxyimidoformamidine is synthesized by the method described in, for example, 001/32164 (disclosed as compound 302).
- the dose varies depending on the disease and the mode of administration, but it is usually 0.1 to 3000 mg, preferably 1 to 300 mg per day.
- Sulfoptyl ether; 8-cyclodextrin or a salt thereof is commercially available (for example, Captiso 1 (registered trademark) (manufactured by CyDex)) or according to the method described in US Pat. It can be obtained by introducing a sulfobutyl group into the H group for synthesis.
- the number of sulfobutyl groups substituted on the OH groups of one molecule of 3-cyclodextrin is called the "degree of substitution", and the average of the degrees of substitution of / 3-cyclodextrin in all molecules is called the "average degree of substitution”. .
- the average degree of substitution is preferably about 5 to about 8, more preferably about 6 to about 7, and even more preferably about 7.
- a pharmaceutically acceptable salt for example, a salt with an alkali metal, particularly, a sodium salt is preferable.
- Sulfobutyl ether) 3-cyclodextrin or a salt thereof is usually from 1.18 to 35.45 mol, relative to 1 mol of N- (3-chloro-4--4-morpholin-4-yl) phenyl-V'-hydroxyimidoformamidine. Preferably, 5.91 to ⁇ 0.7 mol is added.
- Cap tis ⁇ 1® is usually 10 parts by weight based on 1 part by weight of V- (3-chloro-4-morpholine-4-yl) phenyl-T'-hydroxyimidoformamidine. To 300 parts by weight, preferably 50 to 150 parts by weight.
- a pharmaceutically acceptable carrier and other additives such as a tonicity agent (eg, glycerin and glucose), a pH adjuster and the like can be added.
- the pharmaceutical composition of the present invention can be formulated into various pharmaceutical forms such as injection solutions, freeze-dried injections, tablets, granules, powders, capsules, oral liquids, and dry syrups. Is preferred. Injectable solutions and freeze-dried injections are administered by single dose or intravenous drip.
- the pharmaceutical composition of the present invention can be obtained by a usual production method.
- a general manufacturing method for obtaining an injection liquid is as follows: V- (3-chloro-4-4-morpholin-4-yl) phenyl-N'-hydroxyimidoformamidine and sulfobutyl ether ⁇ -cyclodextrin Alternatively, it can be obtained by mixing, stirring and dissolving a salt thereof and water for injection.
- 3-chloro-4-morpholine-4-yl) phenyl-N ' -Hydroxyimidoformamidine and sulfobutyl ether a method of adding and dissolving water for injection to powder of 8-cyclodextrin or a salt thereof, or dissolving sulfoptyl ether) 3-cyclodextrin or a salt thereof in water for injection first.
- a method of adding and dissolving V- (3-chloro-4-4-morpholin-4-yl) phenyl-hydroxyimidoformamidine to the solution.
- An ordinary stirrer can be used for the stirring, but for the purpose of shortening the dissolution time, an emulsifier or a homogenizer using a shearing force or milling power can be used.
- the sterilization process usually includes high-pressure steam sterilization and filtration sterilization.However, in the case of the pharmaceutical composition of the present invention, the high-pressure steam sterilization tends to reduce the drug content. Filtration sterilization is preferred. Usually, a filter having a pore size of about 0.2 mm can be used for filtration sterilization.
- the filter material is not particularly limited as long as it has no adsorption or other problems.
- a general lyophilizer can be used.
- the head space such as vials and ampoules with nitrogen regardless of the liquid state or the freeze-dried state of the composition.
- the pharmaceutical composition of the present invention contains, as shown in the test examples described below, K3-chloro-4-morpholine-4-yl) phenyl-hydroxyimidoformamidine dissolved in a very high concentration.
- the solubility of phenyl-N, -hydroxyimidoformamidine is 3.57 mg / mL (25), and the solubility of the above drug is 7.67 mg / mL (20 w / v% aqueous solution). 25 ° C).
- the solubility of these drugs in 5% Tween80, 10 polyethylene glycol, soybean oil, and olive oil used in the preparation of micelle, cosolvent, and lipid emulsions is 0 ; 5 mg / mL or less ( 25 V). Therefore, the pharmaceutical composition of the present invention can It can be seen that the substance was dissolved and contained significantly higher.
- 8-cyclodextrin sodium salt (Captisol (registered trademark); average degree of substitution is about 7. 110 g) was weighed, 1 L of distilled water for injection was added, and the mixture was dispersed with a stirrer and dissolved using a homogenizer. Thereafter, the solution was filtered and sterilized using a filter having a pore size of 0.22 m. After filling 10 mL of this solution into a 20 mL brown vial, replacing the headspace of the vial with nitrogen, stoppering and tightening, an injection containing 1 mg / mL of the drug was obtained.
- 8-cyclodextrin 100 g and d-mannitol 30 g as an isotonicity agent were used in the same manner as in Example 2 except that A freeze-dried injection of -4-morpholine-4-yl) phenyl-N, -hydroxyimidoformamidine was obtained.
- V_ (3-chloro-4-morpholine-4-yl) phenyl-hydroxyimidoformamidine in purified water as a control was 0.08 mg / mL, as shown in Table 1. Furthermore, it was found that the solubility was improved by adding sulfobutyl ether) 3-cyclodextrin sodium salt to the solution.
- Example 1 Each of the solution of Example 1 and the solution of Comparative Example 1 was placed in a glass tube with a transparent and colorless lid, and stored under a fluorescent condition of 3000 lux, and V- (3-chloro-4--4-morpholine-4-yl) phenyl was added. The residual ratio of benzyl-hydroxyimidoformamidine was determined. As a result, as shown in Table 2, compared with the solution of Comparative Example 1, V- (3-chloro-4--4-morpholin-4-yl) phenyl -'_ hydroxyimidoform in the solution of Example 1 Amidine was extremely stable.
- Example 2 After the lyophilized injection of Example 2 and the lyophilized injection of Comparative Example 2 were stored at 60 to 7 days, the residual ratio of the drug was measured.
- Example 3 As a result, as shown in Table 3, the lyophilized injection of Example 2 was compared with the lyophilized injection of Comparative Example 2 in comparison with V- (3-clo-4--4-morpholin-4-yl) phenyl- V'-hydroxyimidoformamidine was stable. Therefore, it was shown that sulfobutyl ether ⁇ -cyclodextrin is very useful for stabilizing V- (3-chloro-4-morpholine-4-yl) phenyl _′- hydroxyimidoformamidine. Therefore, the freeze-dried injection of the pharmaceutical composition of the present invention was excellent in heat stability and proved to be convenient in actual storage and use. Table 3
- the pharmaceutical composition of the present invention can contain V_ (3-clo-4--4-morpholine-4-yl) phenyl -'- hydroxyimidoformamidine dissolved at a high concentration and is stable over time. It is very convenient for practical use, as it can keep the drug extremely stable against heat, heat and light irradiation.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2486571A CA2486571C (en) | 2002-05-28 | 2003-05-27 | Pharmaceutical composition |
AU2003241800A AU2003241800B2 (en) | 2002-05-28 | 2003-05-27 | Pharmaceutical composition |
JP2004506812A JP4475405B2 (ja) | 2002-05-28 | 2003-05-27 | 医薬組成物 |
MXPA04011777A MXPA04011777A (es) | 2002-05-28 | 2003-05-27 | Composicion farmaceutica. |
EP03730639A EP1508332A4 (en) | 2002-05-28 | 2003-05-27 | MEDICAL COMPOSITION |
HK06101846A HK1081451A1 (en) | 2002-05-28 | 2006-02-13 | Medicinal composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-154624 | 2002-05-28 | ||
JP2002154624 | 2002-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003099288A1 true WO2003099288A1 (fr) | 2003-12-04 |
Family
ID=29561374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/006596 WO2003099288A1 (fr) | 2002-05-28 | 2003-05-27 | Composition medicinale |
Country Status (10)
Country | Link |
---|---|
US (1) | US6818662B2 (ja) |
EP (1) | EP1508332A4 (ja) |
JP (1) | JP4475405B2 (ja) |
CN (1) | CN1290506C (ja) |
AU (1) | AU2003241800B2 (ja) |
CA (1) | CA2486571C (ja) |
HK (1) | HK1081451A1 (ja) |
MX (1) | MXPA04011777A (ja) |
RU (1) | RU2313346C2 (ja) |
WO (1) | WO2003099288A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007004510A1 (ja) * | 2005-06-30 | 2007-01-11 | Taisho Pharmaceutical Co., Ltd. | 脳梗塞治療用の医薬 |
US9186411B2 (en) | 2008-07-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744904B1 (en) * | 2005-09-26 | 2010-06-29 | B.B. Scientific L.L.C. | Stabilization of Clostridium botulinum neurotoxin complex |
WO2008034011A2 (en) | 2006-09-13 | 2008-03-20 | Mcw Research Foundation, Inc. | Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011172A1 (en) * | 1990-01-23 | 1991-08-08 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
WO1994002518A1 (en) * | 1992-07-27 | 1994-02-03 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
JPH092977A (ja) * | 1995-06-21 | 1997-01-07 | Dai Ichi Seiyaku Co Ltd | 経口投与用医薬組成物 |
WO2001032164A1 (fr) * | 1999-11-01 | 2001-05-10 | Taisho Pharmaceutical Co., Ltd. | Inhibiteur pour enzyme de production de 20-hete |
WO2002088071A1 (en) * | 2001-04-26 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | 20-hydroxyeicosatetraenoic acid production inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3502720A (en) * | 1963-12-20 | 1970-03-24 | Schering Ag | N-(2-methyl-4-chlorophenyl)-formamidines |
US4237168A (en) * | 1979-06-11 | 1980-12-02 | The Dow Chemical Company | N-(4-Chloro-2-methylphenyl)-N-hydroxy methanimidamide and its pesticidal use |
DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
US6395781B1 (en) * | 1998-02-26 | 2002-05-28 | Mcw Research Foundation | 20-HETE antagonists and agonists |
-
2002
- 2002-08-14 US US10/217,551 patent/US6818662B2/en not_active Expired - Fee Related
-
2003
- 2003-05-27 CA CA2486571A patent/CA2486571C/en not_active Expired - Fee Related
- 2003-05-27 EP EP03730639A patent/EP1508332A4/en not_active Withdrawn
- 2003-05-27 WO PCT/JP2003/006596 patent/WO2003099288A1/ja active IP Right Grant
- 2003-05-27 MX MXPA04011777A patent/MXPA04011777A/es active IP Right Grant
- 2003-05-27 CN CNB038119900A patent/CN1290506C/zh not_active Expired - Fee Related
- 2003-05-27 JP JP2004506812A patent/JP4475405B2/ja not_active Expired - Lifetime
- 2003-05-27 AU AU2003241800A patent/AU2003241800B2/en not_active Ceased
- 2003-05-27 RU RU2004138299/15A patent/RU2313346C2/ru not_active IP Right Cessation
-
2006
- 2006-02-13 HK HK06101846A patent/HK1081451A1/xx not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011172A1 (en) * | 1990-01-23 | 1991-08-08 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
WO1994002518A1 (en) * | 1992-07-27 | 1994-02-03 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
JPH092977A (ja) * | 1995-06-21 | 1997-01-07 | Dai Ichi Seiyaku Co Ltd | 経口投与用医薬組成物 |
WO2001032164A1 (fr) * | 1999-11-01 | 2001-05-10 | Taisho Pharmaceutical Co., Ltd. | Inhibiteur pour enzyme de production de 20-hete |
WO2002088071A1 (en) * | 2001-04-26 | 2002-11-07 | Taisho Pharmaceutical Co., Ltd. | 20-hydroxyeicosatetraenoic acid production inhibitors |
Non-Patent Citations (1)
Title |
---|
See also references of EP1508332A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007004510A1 (ja) * | 2005-06-30 | 2007-01-11 | Taisho Pharmaceutical Co., Ltd. | 脳梗塞治療用の医薬 |
US9186411B2 (en) | 2008-07-28 | 2015-11-17 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
AU2003241800B2 (en) | 2007-04-19 |
EP1508332A1 (en) | 2005-02-23 |
JPWO2003099288A1 (ja) | 2005-09-22 |
US6818662B2 (en) | 2004-11-16 |
JP4475405B2 (ja) | 2010-06-09 |
CA2486571A1 (en) | 2003-12-04 |
CA2486571C (en) | 2010-04-27 |
HK1081451A1 (en) | 2006-05-19 |
RU2313346C2 (ru) | 2007-12-27 |
EP1508332A4 (en) | 2010-01-13 |
MXPA04011777A (es) | 2005-03-31 |
US20030225032A1 (en) | 2003-12-04 |
AU2003241800A1 (en) | 2003-12-12 |
CN1290506C (zh) | 2006-12-20 |
CN1655790A (zh) | 2005-08-17 |
RU2004138299A (ru) | 2005-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5587198B2 (ja) | タキサン誘導体を含有する、安定性が改良された凍結乾燥医薬組成物、及びその製法 | |
JP4890732B2 (ja) | 癌治療用パクリタキセル・リポソーム組成物およびその製造方法 | |
EP1439830B1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
HU217839B (hu) | Eljárások taxánszármazékokat tartalmazó új stabil gyógyszerkészítmények előállítására | |
US20090182018A1 (en) | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions | |
JP2006008684A (ja) | ジクロフェナクナトリウムとβ−シクロデキストリンとを有する注入可能薬学組成物 | |
US6727286B2 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
AU2002224475A1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
US20060166931A1 (en) | Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
CN113271923A (zh) | 呋塞米的药物组合物及其用途 | |
US20040132823A1 (en) | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid | |
KR101924786B1 (ko) | 이부프로펜의 주사용 약제학적 조성물 | |
WO2008023807A1 (fr) | Composition pharmaceutique stabilisée | |
WO2003099288A1 (fr) | Composition medicinale | |
JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
RU2443432C2 (ru) | Фармацевтическая композиция для введения инъекцией | |
KR20090040299A (ko) | 특별히 표적화된 국소 투여를 위한 주사용 약제학적 조성물 | |
JP6292267B2 (ja) | ドセタキセル製剤 | |
CN101590029B (zh) | 一种丙泊酚组合物 | |
JP2020533318A (ja) | ドセタキセル結合体の医薬組成物及び調製方法 | |
UA75620C2 (en) | Stable pharmaceutical form of paclitaxel and method for the preparation thereof | |
JPH07316065A (ja) | Fr901469物質製剤 | |
JP6033931B2 (ja) | 有機溶媒無含有ゲムシタビン水溶液組成物 | |
RU2545902C1 (ru) | Фармацевтическая композиция в виде лиофилизата с комплексообразующим агентом для приготовления раствора для парентерального применения и способ ее получения | |
JP2015000869A (ja) | 有機溶媒無含有ゲムシタビン水溶液組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003241800 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004506812 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003730639 Country of ref document: EP Ref document number: 2486571 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038119900 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/011777 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2004138299 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2003730639 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003241800 Country of ref document: AU |